Loading…
Risk factors for rifampin-monoresistant tuberculosis : A case-control study
Rifampin is the cornerstone of short-course chemotherapy for the treatment of tuberculosis (TB). Rifampin monoresistance (RMR) is less common than resistance to isoniazid alone or in combination with other antituberculous medications. We conducted a retrospective case-control study to identify risk...
Saved in:
Published in: | American journal of respiratory and critical care medicine 1999-02, Vol.159 (2), p.468-472 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c280t-ac6aa41c136b9afd04f8f3fde52799e3d3da715135457d87c55fa157b57158433 |
container_end_page | 472 |
container_issue | 2 |
container_start_page | 468 |
container_title | American journal of respiratory and critical care medicine |
container_volume | 159 |
creator | SANDMAN, L SCHLUGER, N. W DAVIDOW, A. L BONK, S |
description | Rifampin is the cornerstone of short-course chemotherapy for the treatment of tuberculosis (TB). Rifampin monoresistance (RMR) is less common than resistance to isoniazid alone or in combination with other antituberculous medications. We conducted a retrospective case-control study to identify risk factors for RMR-TB. Complete records for 21 of a total of 26 RMR patients from 1990 to 1997 were available for review, and were compared with those of 48 patients with drug-susceptible TB, controlling for year of diagnosis. Cases more frequently had a history of TB than did controls (61% versus 22%, p < 0.01), and were more often human immunodeficiency virus (HIV) positive (81% versus 46%, p = 0.02). With control for HIV status, cases were more likely to have extrapulmonary involvement (47.6% versus 11.6%, p = 0.05). Four cases (19%) and one control (2. 1%) died (p = 0.02) during hospitalization. Cases more often had a history of incarceration (71.4% versus 37.5%, p = 0.09). Among the 13 cases with a history of TB, five had evidence of malabsorption (vomiting and/or diarrhea), versus none of the 11 controls with prior TB. These data support the hypothesis that RMR is seen primarily in individuals with a history of TB and who are HIV positive. Cases were frequently noncompliant with previous treatment for TB, had a history of incarceration, and had poor outcomes. |
doi_str_mv | 10.1164/ajrccm.159.2.9805097 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69574665</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69574665</sourcerecordid><originalsourceid>FETCH-LOGICAL-c280t-ac6aa41c136b9afd04f8f3fde52799e3d3da715135457d87c55fa157b57158433</originalsourceid><addsrcrecordid>eNpFkE1LwzAYx4Moc06_gUIP4q01aZKm8TaGbzgQRMFbeJYm0Nk2M0kP-_ZGVvT0PPzfDj-ELgkuCKnYLWy91n1BuCzKQtaYYymO0JxwynMmBT5OPxY0Z0x-nqKzELYYk7ImeIZmUpaCcjlHL29t-Mos6Oh8yKzzmW8t9Lt2yHs3OG9CGyIMMYvjxng9di4J2V22zDQEk2s3RO-6LMSx2Z-jEwtdMBfTXaCPh_v31VO-fn18Xi3XuS5rHHPQFQAjmtBqI8E2mNnaUtsYXgopDW1oA4JwQjnjoqmF5twC4WLDk1ozShfo5rC78-57NCGqvg3adB0Mxo1BVZILVlU8BdkhqL0LwRurdr7twe8VweqXoTowVImhKtXEMNWupv1x05vmrzRBS_715EPQ0FkPg27D_7ZIM7WkP8Goe_I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69574665</pqid></control><display><type>article</type><title>Risk factors for rifampin-monoresistant tuberculosis : A case-control study</title><source>Freely Accessible Science Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>SANDMAN, L ; SCHLUGER, N. W ; DAVIDOW, A. L ; BONK, S</creator><creatorcontrib>SANDMAN, L ; SCHLUGER, N. W ; DAVIDOW, A. L ; BONK, S</creatorcontrib><description>Rifampin is the cornerstone of short-course chemotherapy for the treatment of tuberculosis (TB). Rifampin monoresistance (RMR) is less common than resistance to isoniazid alone or in combination with other antituberculous medications. We conducted a retrospective case-control study to identify risk factors for RMR-TB. Complete records for 21 of a total of 26 RMR patients from 1990 to 1997 were available for review, and were compared with those of 48 patients with drug-susceptible TB, controlling for year of diagnosis. Cases more frequently had a history of TB than did controls (61% versus 22%, p < 0.01), and were more often human immunodeficiency virus (HIV) positive (81% versus 46%, p = 0.02). With control for HIV status, cases were more likely to have extrapulmonary involvement (47.6% versus 11.6%, p = 0.05). Four cases (19%) and one control (2. 1%) died (p = 0.02) during hospitalization. Cases more often had a history of incarceration (71.4% versus 37.5%, p = 0.09). Among the 13 cases with a history of TB, five had evidence of malabsorption (vomiting and/or diarrhea), versus none of the 11 controls with prior TB. These data support the hypothesis that RMR is seen primarily in individuals with a history of TB and who are HIV positive. Cases were frequently noncompliant with previous treatment for TB, had a history of incarceration, and had poor outcomes.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><identifier>DOI: 10.1164/ajrccm.159.2.9805097</identifier><identifier>PMID: 9927359</identifier><language>eng</language><publisher>New York, NY: American Lung Association</publisher><subject>Adult ; Aged ; AIDS-Related Opportunistic Infections - diagnosis ; AIDS-Related Opportunistic Infections - drug therapy ; AIDS-Related Opportunistic Infections - microbiology ; AIDS/HIV ; Antibacterial agents ; Antibiotics, Antitubercular - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Case-Control Studies ; CD4 Lymphocyte Count ; Drug Resistance, Microbial ; Female ; Follow-Up Studies ; HIV - immunology ; HIV Seropositivity - diagnosis ; Humans ; Length of Stay ; Male ; Medical sciences ; Middle Aged ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - isolation & purification ; Pharmacology. Drug treatments ; Rifampin - therapeutic use ; Risk Factors ; Treatment Outcome ; Tuberculosis, Pulmonary - diagnosis ; Tuberculosis, Pulmonary - drug therapy ; Tuberculosis, Pulmonary - microbiology</subject><ispartof>American journal of respiratory and critical care medicine, 1999-02, Vol.159 (2), p.468-472</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c280t-ac6aa41c136b9afd04f8f3fde52799e3d3da715135457d87c55fa157b57158433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1705089$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9927359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SANDMAN, L</creatorcontrib><creatorcontrib>SCHLUGER, N. W</creatorcontrib><creatorcontrib>DAVIDOW, A. L</creatorcontrib><creatorcontrib>BONK, S</creatorcontrib><title>Risk factors for rifampin-monoresistant tuberculosis : A case-control study</title><title>American journal of respiratory and critical care medicine</title><addtitle>Am J Respir Crit Care Med</addtitle><description>Rifampin is the cornerstone of short-course chemotherapy for the treatment of tuberculosis (TB). Rifampin monoresistance (RMR) is less common than resistance to isoniazid alone or in combination with other antituberculous medications. We conducted a retrospective case-control study to identify risk factors for RMR-TB. Complete records for 21 of a total of 26 RMR patients from 1990 to 1997 were available for review, and were compared with those of 48 patients with drug-susceptible TB, controlling for year of diagnosis. Cases more frequently had a history of TB than did controls (61% versus 22%, p < 0.01), and were more often human immunodeficiency virus (HIV) positive (81% versus 46%, p = 0.02). With control for HIV status, cases were more likely to have extrapulmonary involvement (47.6% versus 11.6%, p = 0.05). Four cases (19%) and one control (2. 1%) died (p = 0.02) during hospitalization. Cases more often had a history of incarceration (71.4% versus 37.5%, p = 0.09). Among the 13 cases with a history of TB, five had evidence of malabsorption (vomiting and/or diarrhea), versus none of the 11 controls with prior TB. These data support the hypothesis that RMR is seen primarily in individuals with a history of TB and who are HIV positive. Cases were frequently noncompliant with previous treatment for TB, had a history of incarceration, and had poor outcomes.</description><subject>Adult</subject><subject>Aged</subject><subject>AIDS-Related Opportunistic Infections - diagnosis</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>AIDS-Related Opportunistic Infections - microbiology</subject><subject>AIDS/HIV</subject><subject>Antibacterial agents</subject><subject>Antibiotics, Antitubercular - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>CD4 Lymphocyte Count</subject><subject>Drug Resistance, Microbial</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>HIV - immunology</subject><subject>HIV Seropositivity - diagnosis</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Pharmacology. Drug treatments</subject><subject>Rifampin - therapeutic use</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><subject>Tuberculosis, Pulmonary - diagnosis</subject><subject>Tuberculosis, Pulmonary - drug therapy</subject><subject>Tuberculosis, Pulmonary - microbiology</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNpFkE1LwzAYx4Moc06_gUIP4q01aZKm8TaGbzgQRMFbeJYm0Nk2M0kP-_ZGVvT0PPzfDj-ELgkuCKnYLWy91n1BuCzKQtaYYymO0JxwynMmBT5OPxY0Z0x-nqKzELYYk7ImeIZmUpaCcjlHL29t-Mos6Oh8yKzzmW8t9Lt2yHs3OG9CGyIMMYvjxng9di4J2V22zDQEk2s3RO-6LMSx2Z-jEwtdMBfTXaCPh_v31VO-fn18Xi3XuS5rHHPQFQAjmtBqI8E2mNnaUtsYXgopDW1oA4JwQjnjoqmF5twC4WLDk1ozShfo5rC78-57NCGqvg3adB0Mxo1BVZILVlU8BdkhqL0LwRurdr7twe8VweqXoTowVImhKtXEMNWupv1x05vmrzRBS_715EPQ0FkPg27D_7ZIM7WkP8Goe_I</recordid><startdate>19990201</startdate><enddate>19990201</enddate><creator>SANDMAN, L</creator><creator>SCHLUGER, N. W</creator><creator>DAVIDOW, A. L</creator><creator>BONK, S</creator><general>American Lung Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990201</creationdate><title>Risk factors for rifampin-monoresistant tuberculosis : A case-control study</title><author>SANDMAN, L ; SCHLUGER, N. W ; DAVIDOW, A. L ; BONK, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c280t-ac6aa41c136b9afd04f8f3fde52799e3d3da715135457d87c55fa157b57158433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>AIDS-Related Opportunistic Infections - diagnosis</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>AIDS-Related Opportunistic Infections - microbiology</topic><topic>AIDS/HIV</topic><topic>Antibacterial agents</topic><topic>Antibiotics, Antitubercular - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>CD4 Lymphocyte Count</topic><topic>Drug Resistance, Microbial</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>HIV - immunology</topic><topic>HIV Seropositivity - diagnosis</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Pharmacology. Drug treatments</topic><topic>Rifampin - therapeutic use</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><topic>Tuberculosis, Pulmonary - diagnosis</topic><topic>Tuberculosis, Pulmonary - drug therapy</topic><topic>Tuberculosis, Pulmonary - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SANDMAN, L</creatorcontrib><creatorcontrib>SCHLUGER, N. W</creatorcontrib><creatorcontrib>DAVIDOW, A. L</creatorcontrib><creatorcontrib>BONK, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SANDMAN, L</au><au>SCHLUGER, N. W</au><au>DAVIDOW, A. L</au><au>BONK, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for rifampin-monoresistant tuberculosis : A case-control study</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><addtitle>Am J Respir Crit Care Med</addtitle><date>1999-02-01</date><risdate>1999</risdate><volume>159</volume><issue>2</issue><spage>468</spage><epage>472</epage><pages>468-472</pages><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Rifampin is the cornerstone of short-course chemotherapy for the treatment of tuberculosis (TB). Rifampin monoresistance (RMR) is less common than resistance to isoniazid alone or in combination with other antituberculous medications. We conducted a retrospective case-control study to identify risk factors for RMR-TB. Complete records for 21 of a total of 26 RMR patients from 1990 to 1997 were available for review, and were compared with those of 48 patients with drug-susceptible TB, controlling for year of diagnosis. Cases more frequently had a history of TB than did controls (61% versus 22%, p < 0.01), and were more often human immunodeficiency virus (HIV) positive (81% versus 46%, p = 0.02). With control for HIV status, cases were more likely to have extrapulmonary involvement (47.6% versus 11.6%, p = 0.05). Four cases (19%) and one control (2. 1%) died (p = 0.02) during hospitalization. Cases more often had a history of incarceration (71.4% versus 37.5%, p = 0.09). Among the 13 cases with a history of TB, five had evidence of malabsorption (vomiting and/or diarrhea), versus none of the 11 controls with prior TB. These data support the hypothesis that RMR is seen primarily in individuals with a history of TB and who are HIV positive. Cases were frequently noncompliant with previous treatment for TB, had a history of incarceration, and had poor outcomes.</abstract><cop>New York, NY</cop><pub>American Lung Association</pub><pmid>9927359</pmid><doi>10.1164/ajrccm.159.2.9805097</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1073-449X |
ispartof | American journal of respiratory and critical care medicine, 1999-02, Vol.159 (2), p.468-472 |
issn | 1073-449X 1535-4970 |
language | eng |
recordid | cdi_proquest_miscellaneous_69574665 |
source | Freely Accessible Science Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Adult Aged AIDS-Related Opportunistic Infections - diagnosis AIDS-Related Opportunistic Infections - drug therapy AIDS-Related Opportunistic Infections - microbiology AIDS/HIV Antibacterial agents Antibiotics, Antitubercular - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Case-Control Studies CD4 Lymphocyte Count Drug Resistance, Microbial Female Follow-Up Studies HIV - immunology HIV Seropositivity - diagnosis Humans Length of Stay Male Medical sciences Middle Aged Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Pharmacology. Drug treatments Rifampin - therapeutic use Risk Factors Treatment Outcome Tuberculosis, Pulmonary - diagnosis Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology |
title | Risk factors for rifampin-monoresistant tuberculosis : A case-control study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A22%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20rifampin-monoresistant%20tuberculosis%20:%20A%20case-control%20study&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=SANDMAN,%20L&rft.date=1999-02-01&rft.volume=159&rft.issue=2&rft.spage=468&rft.epage=472&rft.pages=468-472&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/10.1164/ajrccm.159.2.9805097&rft_dat=%3Cproquest_cross%3E69574665%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c280t-ac6aa41c136b9afd04f8f3fde52799e3d3da715135457d87c55fa157b57158433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69574665&rft_id=info:pmid/9927359&rfr_iscdi=true |